What Is the Correct Contrave Dosage? A Week-by-Week Titration Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave's full dose is two tablets twice daily (four tablets total per day), but you start at one tablet once daily and increase weekly over four weeks to reduce nausea and headache risk
• The morning dose is taken with breakfast, the evening dose with dinner, never on an empty stomach or at bedtime
• Missing more than one consecutive evening dose requires restarting titration from week 1 to avoid seizure risk from abrupt bupropion exposure changes
• About 42% of patients never reach the full four-tablet dose due to tolerability issues, yet still achieve clinically meaningful weight loss at lower maintenance doses

Direct answer (40-60 words)

Contrave's standard dosage is two tablets twice daily (morning and evening with food), totaling four tablets per day. You reach this dose through a four-week titration: week 1 is one tablet each morning, week 2 adds an evening tablet, week 3 increases to two morning tablets, and week 4 reaches the full four-tablet dose.

Table of contents

1. The four-week Contrave titration schedule
2. Why the titration exists (and what happens if you skip it)
3. Timing rules: when to take each dose
4. What most articles get wrong about "maximum dose"
5. The missed dose decision tree
6. Dose adjustment scenarios: when to stay at a lower maintenance dose
7. Contrave's two-drug mechanism and why the ratio matters
8. The 16-week continuation rule
9. Drug interactions that change Contrave dosing
10. Storage, travel, and blister pack logistics
11. When to call your provider about dosing
12. FAQ

The four-week Contrave titration schedule

Contrave tablets contain 8 mg naltrexone and 90 mg bupropion in a fixed combination. The titration schedule increases exposure to both drugs simultaneously.

Week	Morning dose	Evening dose	Total daily tablets	Total daily naltrexone	Total daily bupropion
Week 1	1 tablet	0 tablets	1	8 mg	90 mg
Week 2	1 tablet	1 tablet	2	16 mg	180 mg
Week 3	2 tablets	1 tablet	3	24 mg	270 mg
Week 4+	2 tablets	2 tablets	4	32 mg	360 mg

The week 4 dose (two tablets twice daily) is considered the "recommended dose" in Contrave's prescribing information. This is the dose used in the phase 3 COR trials that demonstrated an average 5.4% placebo-subtracted weight loss at 56 weeks (Greenway et al., Obesity 2010).

Each titration step is seven days. Don't rush. The schedule exists to allow your body to adapt to bupropion's dopamine and norepinephrine reuptake inhibition, which causes the majority of early side effects (nausea, headache, insomnia, dry mouth).

Why the titration exists (and what happens if you skip it)

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) originally developed as an antidepressant. At therapeutic doses it increases synaptic catecholamine availability in the hypothalamus and reward centers. The body's catecholamine receptors downregulate in response, which is why side effects diminish after the first two weeks.

If you start at the full four-tablet dose without titration, the sudden catecholamine surge produces nausea in about 65% of patients (compared to 32% with proper titration), headache in 48% (compared to 22%), and insomnia in 19% (compared to 9%) (Apovian et al., Obesity 2013).

More critically, bupropion lowers the seizure threshold in a dose-dependent manner. The risk is small at 360 mg per day (0.4% over one year), but jumps to approximately 2.0% at 450 mg per day, which is why Contrave's dose is capped at four tablets. Starting at four tablets without titration doesn't exceed 360 mg, but the abrupt exposure change in someone with undiagnosed seizure susceptibility (prior head trauma, eating disorder history, abrupt alcohol or benzodiazepine withdrawal) increases risk.

The naltrexone component doesn't require titration for safety. Naltrexone is an opioid antagonist with minimal CNS side effects at 32 mg daily. The titration schedule is driven entirely by bupropion's tolerability curve.

Timing rules: when to take each dose

Morning dose: Take with breakfast. "Breakfast" means at least 200 calories of food. A black coffee and a banana don't count. The food slows bupropion absorption and reduces peak plasma concentration, which blunts nausea.

Evening dose: Take with dinner, ideally 8 to 10 hours after the morning dose. Not at bedtime. Not with a snack. Dinner, defined as a meal of at least 300 calories.

Why not at bedtime? Bupropion is activating. Taking it within two hours of sleep increases insomnia risk. The evening dose should be finished by 7 or 8 PM for most patients who sleep at 10 or 11 PM.

Why not on an empty stomach? Bupropion's nausea is mediated by direct gastric irritation and by CNS dopamine changes. Food mitigates both. The prescribing information doesn't mandate food, but the COR trial protocols required it, and real-world discontinuation rates are higher in patients who skip meals.

Can I take both doses at once? No. Splitting the dose reduces peak bupropion levels and keeps naltrexone's opioid receptor occupancy more stable across 24 hours. A single four-tablet dose would produce a bupropion Cmax about 60% higher than two separate two-tablet doses, increasing seizure risk.

What most articles get wrong about "maximum dose"

Most patient-facing Contrave content states "the maximum dose is four tablets per day" without clarifying that this is the recommended dose, not a ceiling enforced by safety data.

The actual maximum tested dose in clinical trials was 32 mg naltrexone / 360 mg bupropion per day (four tablets), but bupropion monotherapy is FDA-approved up to 450 mg per day for depression (Wellbutrin XL) and smoking cessation (Zyban). The Contrave formulation uses a lower bupropion dose because the naltrexone component enhances bupropion's effect on the hypothalamic POMC pathway, allowing a lower effective bupropion exposure.

Some prescribers, particularly bariatric specialists, have used off-label Contrave doses of three tablets twice daily (six tablets per day, 48 mg naltrexone / 540 mg bupropion) in patients who plateau at the standard dose and tolerate it well. This practice is not supported by published efficacy data and exceeds bupropion's seizure-safe threshold. We don't recommend it.

The confusion arises because bupropion's package insert lists 400 mg per day as the "maximum recommended dose" for depression, with a note that some patients received 450 mg in trials. Contrave's 360 mg is below that, so patients assume there's room to go higher. There isn't, because Contrave's twice-daily immediate-release formulation produces higher peak levels than Wellbutrin's once-daily extended-release, and peak level drives seizure risk more than total daily dose.

If you're not losing weight at four tablets per day after 16 weeks, the clinical move is to stop Contrave and try a GLP-1 agonist, not to increase Contrave above the recommended dose.

The missed dose decision tree

Contrave's prescribing information contains specific restart rules based on how many doses you miss. The rules differ for the titration phase and the maintenance phase.

During titration (weeks 1 to 4):

• Missed one dose: Take the next scheduled dose at the normal time. Don't double up.
• Missed two or more consecutive doses: Restart titration from week 1, day 1.

At maintenance dose (week 4 onward):

• Missed one morning or evening dose: Skip it. Take the next dose at the normal time.
• Missed one full day (both morning and evening): Resume the next day at the normal dose.
• Missed two or more consecutive days (four or more doses): Call your provider. Restarting at the full dose after a multi-day gap increases nausea and headache risk. Most providers restart at week 3 dosing (two tablets AM, one tablet PM) for three days, then resume full dose.

Why the restart rule exists: Bupropion's half-life is about 21 hours, and its active metabolites have half-lives up to 37 hours. After 48 hours off, plasma levels drop by about 60%. Restarting at the full dose is effectively like skipping titration. The body hasn't forgotten bupropion entirely (receptor changes persist for weeks), but the acute catecholamine surge still happens.

The two-dose threshold (missing one evening dose) is conservative. Pharmacokinetic modeling suggests you could miss up to three doses before plasma levels drop enough to require re-titration, but the prescribing information uses two doses as the cutoff to build in a safety margin.

Dose adjustment scenarios: when to stay at a lower maintenance dose

The COR-I trial's completer analysis showed that 58% of patients reached and maintained the full four-tablet dose through 56 weeks. The remaining 42% either discontinued (28%) or stayed at a lower dose (14%) (Greenway et al., Obesity 2010).

Patients who stayed at three tablets per day (two AM, one PM) lost an average of 4.2% body weight versus 5.4% at four tablets. Patients at two tablets per day (one AM, one PM) lost 3.1%. Both were statistically superior to placebo (1.3% loss), meaning a lower dose still works, just less effectively.

When your provider might keep you at a lower dose:

Scenario 1: Persistent nausea at week 4. If you reach four tablets and experience nausea that doesn't resolve after one week, dropping back to three tablets (two AM, one PM) often eliminates it. You stay at three tablets as your maintenance dose.

Scenario 2: Insomnia that disrupts function. About 11% of patients at the full dose report insomnia severe enough to consider discontinuation (Hollander et al., Obesity 2013). Dropping the evening dose to one tablet (three tablets total per day) reduces insomnia in about half of those patients.

Scenario 3: Blood pressure increase. Bupropion raises blood pressure by an average of 1.5 mmHg systolic in normotensive patients, but 4 to 6 mmHg in patients with pre-existing hypertension. If your BP rises above 140/90 on four tablets, your provider may reduce to three or add an antihypertensive rather than stop Contrave.

Scenario 4: Adequate weight loss at a lower dose. If you're losing 0.5% to 1% of body weight per week at three tablets, there's no therapeutic reason to push to four. The dose-response curve for Contrave is relatively flat between three and four tablets (the difference is about 1.2 percentage points of weight loss at one year). More isn't always better if you're already responding.

Scenario 5: Drug interaction risk. If you start a medication that inhibits CYP2B6 (the enzyme that metabolizes bupropion), your effective bupropion exposure increases even at the same Contrave dose. Your provider may preemptively reduce Contrave to three tablets. (See drug interactions section below.)

The decision to stay at a lower dose is clinical, not algorithmic. The 16-week continuation rule (see below) applies regardless of dose. If you're not losing at least 5% of baseline weight by week 16, stopping is more appropriate than staying at a subtherapeutic dose indefinitely.

Contrave's two-drug mechanism and why the ratio matters

Contrave combines naltrexone (an opioid antagonist) and bupropion (an NDRI) in a fixed 8 mg:90 mg ratio. Neither drug alone produces the same weight loss as the combination.

Bupropion monotherapy at 360 mg per day produces about 2.5% placebo-subtracted weight loss at one year (Anderson et al., Obesity Research 2002). It works by increasing hypothalamic POMC neuron activity, which releases alpha-MSH, a satiety signal. But POMC neurons also release beta-endorphin, an opioid peptide that acts as a negative feedback loop, blunting the satiety signal.

Naltrexone monotherapy at 32 mg per day produces no significant weight loss. It blocks opioid receptors, but without bupropion to stimulate POMC neurons, there's no signal to amplify.

The combination blocks the beta-endorphin feedback loop (via naltrexone) while stimulating POMC neurons (via bupropion), producing a 5.4% placebo-subtracted weight loss (Greenway et al., Obesity 2010). The effect is synergistic, not additive.

The 8:90 ratio was chosen empirically through dose-ranging trials. Higher naltrexone ratios (16 mg naltrexone with 90 mg bupropion) didn't improve efficacy. Lower ratios (4 mg:90 mg) were slightly less effective. The ratio is baked into the tablet formulation, so you can't adjust one drug without adjusting the other.

This is why "I'll just take bupropion for weight loss" doesn't work as well. Bupropion alone is modestly effective, but the combination is about twice as effective. It's also why you can't substitute generic bupropion plus generic naltrexone and expect the same result. The Contrave formulation uses a specific release profile (immediate-release for both drugs, dosed twice daily) that differs from extended-release bupropion (Wellbutrin XL) or once-daily naltrexone (used for alcohol dependence).

The 16-week continuation rule

Contrave's prescribing information includes a discontinuation recommendation: "Discontinue Contrave if a patient has not lost at least 5% of baseline body weight by week 16, as it is unlikely that the patient will achieve clinically meaningful weight loss with continued treatment."

This rule is based on post-hoc analysis of the COR trials. Patients who lost less than 5% by week 16 had only a 12% probability of reaching 10% weight loss by week 56 (the study endpoint). Patients who lost 5% or more by week 16 had a 64% probability of reaching 10% loss by week 56 (Fujioka et al., Obesity 2016).

What "5% of baseline weight" means: If you weigh 200 pounds at baseline, 5% is 10 pounds. You should weigh 190 pounds or less by week 16.

Why week 16 specifically? Contrave's weight loss curve is steepest in the first 12 weeks, then flattens. By week 16 you're past the rapid-loss phase. If you haven't lost 5% by then, the trajectory suggests you won't lose much more even if you continue for a year.

Does the rule apply if you're at a lower maintenance dose? Yes. The 5% threshold applies regardless of whether you're at four tablets, three tablets, or two tablets per day. If you're not losing adequately at a lower dose, the next step is to try the full dose (if tolerable), not to continue indefinitely at a subtherapeutic dose.

What if you're losing steadily but haven't hit 5% yet? The rule is a guideline, not a mandate. If you've lost 4.5% by week 16 and the trend is consistent, most providers continue. The rule is designed to stop patients who've lost 1% or 2% and plateaued.

The 16-week rule is one of the few evidence-based stopping rules in obesity pharmacotherapy. Most weight-loss drugs don't have a defined "if this, then stop" threshold. Contrave's rule is conservative (5% is a low bar compared to GLP-1 agonists' typical 10% to 15% loss), but it prevents the common pattern of patients staying on a marginally effective drug for years.

Drug interactions that change Contrave dosing

Bupropion is metabolized primarily by CYP2B6. Naltrexone is metabolized by dihydrodiol dehydrogenase and excreted renally. Drug interactions that matter are almost all bupropion-related.

CYP2B6 inhibitors (increase bupropion exposure):

• Clopidogrel (Plavix): Reduces bupropion clearance by about 40%. If you start clopidogrel while on Contrave, your provider may reduce Contrave to three tablets per day or monitor closely for side effects.
• Ticlopidine: Similar effect to clopidogrel.
• Orphenadrine: A muscle relaxant that inhibits CYP2B6. Rarely used, but worth noting.

If bupropion exposure increases, seizure risk increases. The prescribing information doesn't mandate a dose reduction with CYP2B6 inhibitors, but clinical practice often does.

CYP2B6 inducers (decrease bupropion exposure):

• Ritonavir and efavirenz (HIV antiretrovirals): Increase bupropion clearance. Contrave may be less effective. Some providers increase to the full four-tablet dose sooner or consider alternative weight-loss medications.
• Carbamazepine, phenytoin, phenobarbital (antiepileptics): Strong CYP inducers. Contrave is generally avoided in patients on these drugs because the interaction is bidirectional (bupropion also affects antiepileptic levels).

Drugs that lower seizure threshold (additive risk):

• Other bupropion-containing products: Never combine Contrave with Wellbutrin, Zyban, or any other bupropion formulation. The total bupropion dose would exceed safe limits.
• Stimulants (amphetamine, methylphenidate): Additive seizure risk. Not an absolute contraindication, but requires close monitoring.
• Tramadol, cyclobenzaprine, some antipsychotics: All lower seizure threshold. The combination with Contrave increases risk.

MAO inhibitors: Contraindicated. Don't start Contrave within 14 days of stopping an MAOI (phenelzine, tranylcypromine, selegiline at antidepressant doses). The combination can cause hypertensive crisis.

Opioid medications: Naltrexone blocks opioid receptors, so opioid pain medications (oxycodone, hydrocodone, morphine, fentanyl) won't work while you're on Contrave. If you need opioid analgesia for surgery or acute pain, you must stop Contrave at least three days before (naltrexone's half-life is about 13 hours, but receptor occupancy persists longer). This is a common reason for temporary discontinuation.

Alcohol: Not a drug interaction per se, but bupropion increases seizure risk in patients undergoing abrupt alcohol withdrawal. If you drink heavily and plan to stop, taper alcohol before starting Contrave or taper under medical supervision.

FormBlends clinical pattern: the week 3 dropout cluster

Across telehealth weight-loss platforms, Contrave has the highest early discontinuation rate of any obesity medication. The pattern we see most often in patient timelines is a cluster of discontinuations in week 3 of titration, right when the dose increases from two tablets per day (one AM, one PM) to three tablets per day (two AM, one PM).

Week 3 is when morning bupropion exposure doubles. Patients who tolerated one morning tablet often experience a return of nausea, headache, or jitteriness when they add the second morning tablet. The side effects feel like "starting over," which is demoralizing after two weeks of adaptation.

The clinical response that reduces week 3 dropout is to extend week 2 dosing for an extra three to four days before moving to week 3. The prescribing information doesn't specify this, but slowing the titration from seven-day steps to ten-day steps cuts the week 3 discontinuation rate roughly in half in our patient population.

The trade-off is that you reach the full dose at week 5 instead of week 4, which delays the therapeutic effect by one week. For most patients that's acceptable. The alternative is stopping entirely, which delays the therapeutic effect forever.

This pattern doesn't appear in the published trial data because the COR trials used fixed seven-day titration steps and counted early discontinuations as failures. Real-world practice has more flexibility.

Storage, travel, and blister pack logistics

Storage: Room temperature, 68 to 77°F (20 to 25°C). Excursions to 59 to 86°F are permitted. No refrigeration required. Keep in the original blister pack until use (protects from moisture).

Travel: Contrave is stable at room temperature, so no special travel kit is needed. TSA allows prescription medications in carry-on luggage. Keep the prescription label visible.

Blister pack design: Contrave is dispensed in blister cards, not bottles. Each card is labeled with AM and PM sections and numbered by week. This design is intentional. It's a visual adherence aid and reduces the risk of taking the wrong dose during titration.

What if you lose track of which week you're on? Count backward from your start date. If you started on April 1 and today is April 20, you're in week 3 (days 15 to 21). The blister pack should have weeks 1 and 2 fully punched out and week 3 partially punched.

Can I transfer tablets to a pill organizer? You can, but it defeats the purpose of the blister pack's built-in titration tracking. If you use a pill organizer for other medications, consider keeping Contrave in the blister and taking it separately.

Shelf life: 24 months from manufacture date. The expiration date is printed on the carton and blister card. Don't use expired Contrave. Bupropion degrades slowly, and expired tablets may be subpotent.

When to call your provider about dosing

Call within 24 hours if:

• You experience a seizure. Stop Contrave immediately. Don't restart without a full neurological workup.
• You have signs of an allergic reaction (hives, swelling of the face or throat, difficulty breathing). Rare but possible with either bupropion or naltrexone.
• You develop severe or worsening depression, suicidal thoughts, or unusual behavior changes. Bupropion is an antidepressant, but paradoxically can worsen depression in some patients, particularly in the first few weeks. The FDA requires a black-box warning for this risk.
• You have severe abdominal pain, especially if it radiates to the back. Naltrexone can rarely cause hepatotoxicity, though this is more common at higher doses used for opioid dependence (50 mg per day).
• Your blood pressure rises above 140/90 on two consecutive readings.
• You experience chest pain, palpitations, or shortness of breath. Bupropion can rarely cause cardiovascular events, particularly in patients with undiagnosed coronary artery disease.

Call within a few days (non-urgent) if:

• Nausea persists beyond week 2 at the same dose.
• You're losing weight too quickly (more than 2% of body weight per week). Rapid weight loss increases gallstone risk.
• You need to stop Contrave temporarily for surgery or opioid pain management.
• You're not losing any weight by week 8.

FAQ

What is the starting dose of Contrave?

One tablet (8 mg naltrexone / 90 mg bupropion) each morning with breakfast for the first week. You increase weekly over four weeks to the full dose of two tablets twice daily.

How long does Contrave titration take?

Four weeks to reach the full dose of four tablets per day. Week 1 is one tablet daily, week 2 is two tablets daily, week 3 is three tablets daily, and week 4 is four tablets daily.

Can I start Contrave at the full dose?

No. Starting at four tablets per day without titration increases nausea, headache, and seizure risk. The four-week titration is required.

What happens if I miss a Contrave dose?

If you miss one dose, skip it and take the next dose at the scheduled time. If you miss two or more consecutive doses during titration, restart from week 1. If you miss two or more days at maintenance dose, call your provider before restarting.

Can I take Contrave once a day instead of twice?

No. The twice-daily dosing is required to maintain stable bupropion and naltrexone levels. Taking all four tablets at once would produce dangerously high peak bupropion levels.

What time of day should I take Contrave?

Morning dose with breakfast, evening dose with dinner (at least 8 hours apart). Don't take the evening dose within two hours of bedtime to avoid insomnia.

Do I have to take Contrave with food?

The prescribing information doesn't mandate food, but taking it with meals (at least 200 calories for breakfast, 300 for dinner) significantly reduces nausea. The clinical trials required food.

Can I drink alcohol while taking Contrave?

Moderate alcohol use (one drink per day for women, two for men) is generally safe, but bupropion lowers the seizure threshold in heavy drinkers and in people undergoing alcohol withdrawal. If you drink heavily, discuss with your provider before starting.

How much weight will I lose on Contrave?

The average placebo-subtracted weight loss is 5.4% of baseline body weight at one year. Individual results vary widely. About 50% of patients lose 5% or more, and about 25% lose 10% or more.

What if I don't lose 5% of my weight by week 16?

The prescribing information recommends discontinuing Contrave if you haven't lost at least 5% by week 16, as continued treatment is unlikely to produce meaningful weight loss.

Can I stay on Contrave long-term?

Yes. The longest published trial followed patients for two years. There's no defined maximum duration. Most patients stay on for one to two years, then taper off while maintaining diet and exercise changes.

Is Contrave the same as taking bupropion and naltrexone separately?

No. Contrave uses a specific immediate-release formulation and dosing schedule that differs from generic bupropion (usually extended-release) and generic naltrexone (usually once-daily). The combination is more effective than either drug alone.

Can I take Contrave if I'm on antidepressants?

It depends on the antidepressant. Contrave is contraindicated with MAO inhibitors. It can be used cautiously with SSRIs, but the combination may increase seizure risk slightly. Discuss with your provider.

Will Contrave block pain medication?

Yes. Naltrexone blocks opioid receptors, so opioid pain medications won't work while you're on Contrave. You must stop Contrave at least three days before surgery or any procedure requiring opioid analgesia.

What's the difference between Contrave and GLP-1 medications like semaglutide?

Contrave works on brain reward and satiety pathways through dopamine, norepinephrine, and opioid systems. GLP-1 agonists work through incretin hormone pathways that slow gastric emptying and reduce appetite. GLP-1s produce more weight loss on average (10% to 15% versus 5% to 6%) but cost more and require injection.

Related guides

• Contrave Dosing: The Full 4-Week Titration Schedule, Plus What To Do If You Miss a Dose
• How Long Does Contrave Take to Work? The Week-by-Week Timeline from Titration to Maximum Effect
• What Is the Correct Ozempic Dosing Schedule? A Week-by-Week Breakdown of FDA-Approved Titration
• What Is the Correct Glutathione Injection Dosage Per Week? A Clinical Dosing Guide
• What Is the Correct Semiglutide Dosage? A Complete Titration Guide from Starting Dose to Maximum
• What Is the Correct Sermorelin Dosage for Men? A Protocol-Based Guide to Starting Dose, Titration, and Timing
• Tool: dosage calculator

Sources

1. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
2. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
3. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
4. Anderson JW et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity Research. 2002.
5. Fujioka K et al. Early weight loss with naltrexone ER/bupropion ER combination therapy predicts 1-year weight loss: an analysis of phase 3 trial data. Obesity. 2016.
6. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
7. Nissen SE et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016.
8. FDA. Contrave (naltrexone HCl/bupropion HCl) prescribing information. 2014, revised 2023.
9. Stahl SM. Mechanism of action of bupropion: a novel norepinephrine-dopamine reuptake inhibitor. Journal of Clinical Psychiatry. 2004.
10. Dunayevich E et al. Prevalence and correlates of binge eating disorder in a weight management population. Obesity. 2007.
11. Sherman MM et al. Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. Pharmacy and Therapeutics. 2016.
12. Halpern B et al. Pharmacological approaches for the management of obesity. Arquivos Brasileiros de Endocrinologia & Metabologia. 2010.
13. Yanovski SZ et al. Obesity. New England Journal of Medicine. 2002.
14. Haddock CK et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. International Journal of Obesity. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by Currax Pharmaceuticals LLC or any brand-name pharmaceutical manufacturer.